期刊文献+

单纯疱疹病毒1型糖蛋白B胞外区基因片段的克隆、表达及初步鉴定 被引量:1

Cloning,Expression and Initial Identification of Extracellular Region Gene Fragment of Herpes Simplex Viruses l
下载PDF
导出
摘要 构建单纯疱疹病毒1型糖蛋白B(HSV1gB)胞外区基因片段的重组原核表达质粒,并获得HSV1gB胞外区基因的表达。选用真核和原核细胞均偏爱的密码子,化学合成含信号肽序列的HSV1gB蛋白胞外区基因序列,用PCR方法扩增编码HSV1gB胞外区1~696aa的基因,利用DNA重组技术将其定向插入到原核表达载体pGEX4T-2上,转化大肠杆菌TG1菌株,经IPTG诱导表达及SDS-PAGE鉴定分析。SDS-PAGE检测显示,表达的HSV1gB/GST融合蛋白分子质量为96ku。利用亲和层析方法,纯化获得了表达的目的蛋白。ELISA结果表明表达产物具有较好的抗原性和特异性。可溶性重组HSV1gB蛋白的表达成功为单纯疱疹病毒亚单位疫苗的研究奠定了基础。 To construct the recombinant plasmid expressing extracellular region gene fragment of herpes simplex viruses 1 glycoprotein B and to acquire the protein. The extracellular region of the herpes simplex viruses 1 glyco protein B gene was amplified by PCR and was cloned into plasmid pGEX4T-2 by T4 ligase. The ligated products were transformed into E. coli TG1. The transformants were induced by IPTG and identified by SDS-PAGE for screening the positive transformants. The recombinant plasmid HSVlgB-pGEX4T-2 expressing HSVlgB was successfully constructed, which could distinctively express the HSVlgB/GST. ELISA result showed that the expressed 96kd HSVlgB chimeric protein has good antigenicity and specificity, which have established the foundation for developing herpes simplex viruses subunit vaccine.
出处 《药物生物技术》 CAS CSCD 2008年第2期90-93,共4页 Pharmaceutical Biotechnology
基金 国家"863"计划项目资金资助(2006AA02A226)
关键词 单纯疱疹病毒 糖蛋白B 克隆 表达 Herpes simplex virus (HSV), Glycoprotein B(gB), Cloning, Expression
  • 相关文献

参考文献13

  • 1Stanberry LR, Jorgensen BM, Nahmias AJ. Herpes simplex viruses 1 and 2. In: Evand AS, koslow RA, editors. Viral infections of humans : epidemiology and control [M]. 4th ed. New York: plenum Medical Book Company 1997, 419.
  • 2Nahmias AJ, Bannenbarger J, Wickliffe C, et al. Clinical aspects of infection with herpes simplex viruses 1 and 2[M]. In Nahmias A J, BowBle WR, Schinazi RE:The human herpes viruses :An Interdisciplinary persoective Elsevier Press, Amsterdam 1980,3.
  • 3杨慧兰.生殖器疱疹疫苗的研究进展[J].国外医学(皮肤性病学分册),1998,24(5):280-282. 被引量:14
  • 4Richard JW, Kaiwar R, Nesburn AD, etal. Herpes simplex virus infections[J]. Lantet 2001,357:1513.
  • 5Baghian A, Chouljenko VN, Dauvergne O, et al. Protective immunity against lethal HSV-1 challenge in mice by nucleicacid-based immunization with heropes simlex virus type-1 genes specifying glycoproteins gB and gD[J].J Med Microbiol, 2002,51(4) :350.
  • 6Stanberry LR. Glycoprotein-D-adjuvant vaccine to prevent genital herpes[J]. N Engl J Med,2002,347:1652.
  • 7Manservigi R, Boero A, Argnani R, etal. Immunotherapeu tic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV2 infections in a guinea pig model[J]. Vaccine, 2005, 23(7):865.
  • 8Orr MT, Orgun NN, Wilson CB, et al. Cutting Edge: Recombinant Listeria monocytogenes expressing a single irnmune-dominant peptide confers protective immunity to herpes simplex virus- 1 infection[J]. J Immunol, 2007,178(8) :4731.
  • 9Bamdad T, Roostaee MH, Sadeghizadeh M, et al. Immuno genicity and protective effect of a DNA construct encoding certain neutralizing epitopes of herpes simplex virus type-1 glycoprotein B[J]. Folia Biol (Praha), 2005,51(4) : 109.
  • 10Pellett PE, Kousoulas KG, PereiraL, et al. Anatomy of the her pes simplex virus I strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistantmutants[J]. J Virol , 1985,53(1):243.

二级参考文献18

  • 1Corey L. Sex Transm Dis, 1994:21:s38-s44.
  • 2Bernstein DI et al. J Med Virol, 1990;30(1):45-49.
  • 3Blacklaws BA et al. Virology, 1990; 177(2):727-736.
  • 4Johnson DC et al. Rev Infect Dis, 1991; 13(s11):s912-s916.
  • 5Galloway DA. J Med Virol, 1990;31(1):36-42.
  • 6Watson RJ. Science, 1982;2218(22):381-384.
  • 7Miriagou V et al. J Gen Virol, 1995;76(12):3137.
  • 8Krishan S et al. J Gen Virol, 1989;70:1806.
  • 9Ghiasi H et al. Vaccine, 1996;14(2):107-112.
  • 10Baynestad K et al. J Virol, 1994;64:680-685.

共引文献13

同被引文献22

  • 1杨慧兰,周翠,关蕾,赵举峰,樊建勇.单纯疱疹病毒II型CTL表位DNA疫苗的Th1/Th2免疫应答研究[J].中国皮肤性病学杂志,2007,21(7):402-404. 被引量:5
  • 2Eizuru Y. Development of new antivirals for herpesviruses. Antivir Chem Chemother, 2003, 14 (6) :299-308.
  • 3Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a metaanalysis. J Infect Dis, 2002, 185(1) :45-52.
  • 4Perez G, Skumick J H, Denny T N, et al. Herpes simplex type Ⅱ and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis, 1998, 3(1) :5-11.
  • 5Chen C Y, Ballard R C, Beck-Sague C M, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis, 2000, 27 ( 1 ) : 21-29.
  • 6Langenberg A G M, Burke R L, Adair S F, et al. A recombinant glycoprotein vaccine for herpes simplex type2 : safety and efficacy. Ann Intern Med, 1995, 122(12):889-898.
  • 7Ashley R L, Wald A. Genital herpes: review of the epidemic and potential use of type-specific serology. Clin Microbiol Rev, 1999, 12(1):1-8.
  • 8Stanberry L, Cunningham A, Mertz G, et al. New developments in the epidemiology, natural history, and management of genital herpes. Antiviral Res, 1999, 42(1) :1-14.
  • 9Fleming D T, McQuillan G M, Johnson R E, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med, 1997, 337(16) :1105-1111.
  • 10Ribes J A, Steele A D, Seabolt J P, et al. Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol, 2001, 39(9) :3321-3325.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部